Search research articles
Contact Us
Filters
Showing results (101-110 of 140) with videos related to
Page
of 14
Sort By:
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Gynecologic Oncology
|
November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Julia L Boland, Qin Zhou, Madhuri Martin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Tiffany Y Sia, Vivian Wan, Michael Finlan, et al.
Cancer
|
December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M Rubinstein, David M Hyman, Imogen Caird, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 31, 2024
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Tiffany Y Sia, Vivian Wan, Michael Finlan, et al.
Journal of Gynecologic Oncology
|
February 1, 2024
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, et al.
International Journal of Cancer
|
November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
JCO Precision Oncology
|
October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification
William A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology
|
December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Maria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 140) with videos related to
Sort By:
Page
of 14
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Gynecologic Oncology
|
November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Julia L Boland, Qin Zhou, Madhuri Martin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Tiffany Y Sia, Vivian Wan, Michael Finlan, et al.
Cancer
|
December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M Rubinstein, David M Hyman, Imogen Caird, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 31, 2024
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Tiffany Y Sia, Vivian Wan, Michael Finlan, et al.
Journal of Gynecologic Oncology
|
February 1, 2024
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, et al.
International Journal of Cancer
|
November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
JCO Precision Oncology
|
October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification
William A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology
|
December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Maria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Page
of 14